Vascular permeability factor/vascular endothelial growth factor and its receptors: Evolving paradigms in vascular biology and cell signaling

Debabrata Mukhopadhyay, Resham Bhattacharya, Deborah A. Hughes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

VASCULAR ENDOTHELIAL GROWTH FACTORS Background and Discovery The pioneering observations of Dvorak and his group first showed that tumor ascites fluids from guinea pigs, hamsters, and mice contained an activity that rapidly increased micro-vascular permeability. The permeability-increasing activity purified from either the culture medium or ascites fluid of one tumor – the guinea pig line 10 hepatocarcinoma – was a 34,000-to 42,000-dalton protein that was distinct from other known permeability factors (1).The vascular permeability factor (VPF) was also secreted by five human tumor cell lines and could be eluted from immobilized heparin. Two tumorigenic (in nude mice) human cell lines were found to secrete at least 14-fold more VPF than their directly matched, nontumorigenic counterparts, suggesting that this factor was important for tumor growth (2). Later Ferrara and colleagues, and others, isolated a heparin-binding growth factor from the conditioned media of bovine pituitary follicular cells (FCs) and described it as vascular endothelial growth factor (VEGF). This factor was specific for vascular endothelial cells (ECs) and was able to induce angiogenesis in vivo. Complementary DNA (cDNA) clones for bovine and human VEGF were isolated from cDNA libraries prepared from FC and HL60 leukemia cells, and it was subsequently recognized that VPF and VEGF were encoded by a single gene (3–7). Gene and Splice Variants The human VEGF gene, located on the short arm of chromosome 6, is comprised of eight exons (8) and gives rise to five isoforms containing 121, 145, 165, 189, and 206 amino acids, respectively, that are produced as a result of alternate splicing (9–11). The full transcript encodes a 189-amino acid isoform.

Original languageEnglish (US)
Title of host publicationEndothelial Biomedicine
PublisherCambridge University Press
Pages266-284
Number of pages19
Volume9780521853767
ISBN (Print)9780511546198, 0521853761, 9780521853767
DOIs
StatePublished - Jan 1 2007

Fingerprint

Cell signaling
Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
Blood Vessels
Cell Biology
Tumors
Genes
Ascites
Heparin
Permeability
Protein Isoforms
Guinea Pigs
Complementary DNA
Vascular Endothelial Growth Factors
Cells
Amino Acids
Neoplasms
Chromosomes, Human, Pair 6
Fluids
HL-60 Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mukhopadhyay, D., Bhattacharya, R., & Hughes, D. A. (2007). Vascular permeability factor/vascular endothelial growth factor and its receptors: Evolving paradigms in vascular biology and cell signaling. In Endothelial Biomedicine (Vol. 9780521853767, pp. 266-284). Cambridge University Press. https://doi.org/10.1017/CBO9780511546198.033

Vascular permeability factor/vascular endothelial growth factor and its receptors : Evolving paradigms in vascular biology and cell signaling. / Mukhopadhyay, Debabrata; Bhattacharya, Resham; Hughes, Deborah A.

Endothelial Biomedicine. Vol. 9780521853767 Cambridge University Press, 2007. p. 266-284.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mukhopadhyay, Debabrata ; Bhattacharya, Resham ; Hughes, Deborah A. / Vascular permeability factor/vascular endothelial growth factor and its receptors : Evolving paradigms in vascular biology and cell signaling. Endothelial Biomedicine. Vol. 9780521853767 Cambridge University Press, 2007. pp. 266-284
@inbook{5f9347fa18eb43009e845d30caddf866,
title = "Vascular permeability factor/vascular endothelial growth factor and its receptors: Evolving paradigms in vascular biology and cell signaling",
abstract = "VASCULAR ENDOTHELIAL GROWTH FACTORS Background and Discovery The pioneering observations of Dvorak and his group first showed that tumor ascites fluids from guinea pigs, hamsters, and mice contained an activity that rapidly increased micro-vascular permeability. The permeability-increasing activity purified from either the culture medium or ascites fluid of one tumor – the guinea pig line 10 hepatocarcinoma – was a 34,000-to 42,000-dalton protein that was distinct from other known permeability factors (1).The vascular permeability factor (VPF) was also secreted by five human tumor cell lines and could be eluted from immobilized heparin. Two tumorigenic (in nude mice) human cell lines were found to secrete at least 14-fold more VPF than their directly matched, nontumorigenic counterparts, suggesting that this factor was important for tumor growth (2). Later Ferrara and colleagues, and others, isolated a heparin-binding growth factor from the conditioned media of bovine pituitary follicular cells (FCs) and described it as vascular endothelial growth factor (VEGF). This factor was specific for vascular endothelial cells (ECs) and was able to induce angiogenesis in vivo. Complementary DNA (cDNA) clones for bovine and human VEGF were isolated from cDNA libraries prepared from FC and HL60 leukemia cells, and it was subsequently recognized that VPF and VEGF were encoded by a single gene (3–7). Gene and Splice Variants The human VEGF gene, located on the short arm of chromosome 6, is comprised of eight exons (8) and gives rise to five isoforms containing 121, 145, 165, 189, and 206 amino acids, respectively, that are produced as a result of alternate splicing (9–11). The full transcript encodes a 189-amino acid isoform.",
author = "Debabrata Mukhopadhyay and Resham Bhattacharya and Hughes, {Deborah A.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511546198.033",
language = "English (US)",
isbn = "9780511546198",
volume = "9780521853767",
pages = "266--284",
booktitle = "Endothelial Biomedicine",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Vascular permeability factor/vascular endothelial growth factor and its receptors

T2 - Evolving paradigms in vascular biology and cell signaling

AU - Mukhopadhyay, Debabrata

AU - Bhattacharya, Resham

AU - Hughes, Deborah A.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - VASCULAR ENDOTHELIAL GROWTH FACTORS Background and Discovery The pioneering observations of Dvorak and his group first showed that tumor ascites fluids from guinea pigs, hamsters, and mice contained an activity that rapidly increased micro-vascular permeability. The permeability-increasing activity purified from either the culture medium or ascites fluid of one tumor – the guinea pig line 10 hepatocarcinoma – was a 34,000-to 42,000-dalton protein that was distinct from other known permeability factors (1).The vascular permeability factor (VPF) was also secreted by five human tumor cell lines and could be eluted from immobilized heparin. Two tumorigenic (in nude mice) human cell lines were found to secrete at least 14-fold more VPF than their directly matched, nontumorigenic counterparts, suggesting that this factor was important for tumor growth (2). Later Ferrara and colleagues, and others, isolated a heparin-binding growth factor from the conditioned media of bovine pituitary follicular cells (FCs) and described it as vascular endothelial growth factor (VEGF). This factor was specific for vascular endothelial cells (ECs) and was able to induce angiogenesis in vivo. Complementary DNA (cDNA) clones for bovine and human VEGF were isolated from cDNA libraries prepared from FC and HL60 leukemia cells, and it was subsequently recognized that VPF and VEGF were encoded by a single gene (3–7). Gene and Splice Variants The human VEGF gene, located on the short arm of chromosome 6, is comprised of eight exons (8) and gives rise to five isoforms containing 121, 145, 165, 189, and 206 amino acids, respectively, that are produced as a result of alternate splicing (9–11). The full transcript encodes a 189-amino acid isoform.

AB - VASCULAR ENDOTHELIAL GROWTH FACTORS Background and Discovery The pioneering observations of Dvorak and his group first showed that tumor ascites fluids from guinea pigs, hamsters, and mice contained an activity that rapidly increased micro-vascular permeability. The permeability-increasing activity purified from either the culture medium or ascites fluid of one tumor – the guinea pig line 10 hepatocarcinoma – was a 34,000-to 42,000-dalton protein that was distinct from other known permeability factors (1).The vascular permeability factor (VPF) was also secreted by five human tumor cell lines and could be eluted from immobilized heparin. Two tumorigenic (in nude mice) human cell lines were found to secrete at least 14-fold more VPF than their directly matched, nontumorigenic counterparts, suggesting that this factor was important for tumor growth (2). Later Ferrara and colleagues, and others, isolated a heparin-binding growth factor from the conditioned media of bovine pituitary follicular cells (FCs) and described it as vascular endothelial growth factor (VEGF). This factor was specific for vascular endothelial cells (ECs) and was able to induce angiogenesis in vivo. Complementary DNA (cDNA) clones for bovine and human VEGF were isolated from cDNA libraries prepared from FC and HL60 leukemia cells, and it was subsequently recognized that VPF and VEGF were encoded by a single gene (3–7). Gene and Splice Variants The human VEGF gene, located on the short arm of chromosome 6, is comprised of eight exons (8) and gives rise to five isoforms containing 121, 145, 165, 189, and 206 amino acids, respectively, that are produced as a result of alternate splicing (9–11). The full transcript encodes a 189-amino acid isoform.

UR - http://www.scopus.com/inward/record.url?scp=84928859549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928859549&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511546198.033

DO - 10.1017/CBO9780511546198.033

M3 - Chapter

AN - SCOPUS:84928859549

SN - 9780511546198

SN - 0521853761

SN - 9780521853767

VL - 9780521853767

SP - 266

EP - 284

BT - Endothelial Biomedicine

PB - Cambridge University Press

ER -